Join to View Full Profile
1110 Oak StAlyce Elmore Kraemer Cancer Care CenterWest Bend, WI 53095
Phone+1 262-334-8484
Fax+1 414-805-4944
Dr. Kamaraju is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1999 - 2002
Hennepin HealthcareResidency, Internal Medicine, 1996 - 1999
University of Arizona College of Medicine-Tucson (South Campus)Internship, Internal Medicine, 1995 - 1996
Guntur Medical College NTRClass of 1993
Certifications & Licensure
WI State Medical License 2002 - 2025
TX State Medical License 2008 - 2015
MN State Medical License 1998 - 2005
IL State Medical License 2002 - 2002
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Start of enrollment: 2010 Oct 12
- Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) Start of enrollment: 2021 Oct 05
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer Start of enrollment: 2022 Mar 07
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsA Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.Sailaja Kamaraju, Amy M Fowler, Sergey Tarima, Lubna N Chaudhary, Mark E Burkard
Clinical Breast Cancer. 2025-04-01 - The association of distress and depression screening measures and other electronic health record information with adjuvant endocrine therapy persistence.Joan M Neuner, Melinda Stolley, Sailaja Kamaraju, Jacob Tiegs, Rodney Sparapani
Breast Cancer Research and Treatment. 2025-02-01 - 2 citationsEquitable community-based participatory research engagement with communities of color drives All of Us Wisconsin genomic research priorities.Suma K Thareja, Xin Yang, Paramita Basak Upama, Aziz Abdullah, Shary Pérez Torres
Journal of the American Medical Informatics Association. 2024-12-01
Press Mentions
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast CancerDecember 11th, 2024- Context Therapeutics® to Present Clinical Data on ONA-XR in Breast Cancer at 2021 San Antonio Breast Cancer SymposiumNovember 19th, 2021
Context Therapeutics and Wisconsin Oncology Network (WON) to Evaluate Apristor Combination Therapy for Women with Advanced Breast CancerOctober 7th, 2019
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
